Leukemia Research
Volume 26, Issue 11 , Pages 971-973 , November 2002

Bcr/Abl, leukemogenesis, and genomic instability: a complex partnership

Received 10 October 2001 ,Accepted 10 October 2001.

References 

  1. Bernstein R. Cytogenetics of chronic myelogenous leukemia. Semin. Hematol. 1988;25:20
  2. Voncken JW, Morris C, Pattengale P, Dennert G, Kikly C, Groffen J, et al.  Clonal development and karyotype evolution during leukemogenesis of BCR/ABL transgenic mice. Blood. 1992;79:1029
  3. Laneuville P, Sun G, Timm M, Vekemans M. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl. Blood. 1992;80:1788
  4. Mertens F, Johansson B, Hoglund M, Mitelman F. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res. 1997;57:2765
  5. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukemia in bcr/abl transgenic mice. Nature. 1990;344:251
  6. Provost GS, Kretz PL, Hamner RT, Matthews CD, Rogers BJ, Lundberg KS, et al.  Transgenic systems for in vivo mutation analysis. Mutat. Res. 1993;288:133
  7. Salloukh HF, Laneuville P. Increase in mutant frequencies in mice expressing the BCR/ABL activated tyrosine kinase. Leukemia. 2000;14:1401
  8. Brain JM, Saksena A, Laneuville P. The kinase inhibitor STI571 reverses the Bcr/Abl induced point mutation frequencies observed in pre-leukemic P190Bcr/Abl transgenic mice. Leukemia Res, 2001.
  9. Kharbanda S, Ren R, Pandey P, Shafman TD, Feller SM, Weichselbaum RR, et al.  Activation of the c-Abl tyrosine kinase in the stress response to DNA–damaging agents. Nature. 1995;376:785
  10. Yuan Z M, Huang Y, Whang Y, Sawyers C, Weichselbaum R, Kharbanda S, et al.  Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature. 1996;382:272
  11. Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T, et al.  Interaction between ATM protein and c-Abl in response to DNA damage. Nature. 1997;387:520
  12. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y, et al.  Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature. 1997;387:516
  13. Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, Kharbanda S, et al.  Regulation of Rad51 function by c-Abl in response to DNA damage. J. Biol. Chem. 1998;273:3799
  14. Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J. Biol. Chem. 2000;275:39223
  15. Wang JY. Regulation of cell death by the Abl tyrosine kinase. Oncogene. 2000;19:5643
  16. Canitrot Y, Lautier D, Laurent G, Frechet M, Ahmed A, Turhan AG, et al.  Mutator phenotype of BCR/ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene. 1999;18:2676
  17. Kunkel TA. The mutational specificity of DNA polymerase-beta during in vitro DNA synthesis. Production of frameshift, base substitution, and deletion mutations. J. Biol. Chem. 1985;260:5787
  18. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996;2:561
  19. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al.  Clinical resistance to STI-571 cancer therapy caused by BCR/ABL gene mutation or amplification. Science. 2001;293:876

PII: S0145-2126(01)00180-1

Leukemia Research
Volume 26, Issue 11 , Pages 971-973 , November 2002

Article Tools